Ronald Blue Trust, Inc. Mirati Therapeutics, Inc. Transaction History

Ronald Blue Trust, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	SELL	$41.99 - $62.38 $1,133 - $1,684	-27 Reduced 33.75%	53 $2,000
Q2 2023 Jul 14, 2023	SELL	$36.13 - $49.49 $289 - $395	-8 Reduced 9.09%	80 $3,000
Q1 2023 Apr 17, 2023	BUY	$36.54 - $54.26 $2,959 - $4,395	81 Added 1157.14%	88 $4,000
Q4 2022 Jan 17, 2023	SELL	$41.27 - $98.62 $701 - $1,676	-17 Reduced 70.83%	7 $0
Q3 2022 Oct 21, 2022	BUY	$59.5 - $86.7 $1,428 - $2,080	24 New	24 $2,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

Stay updated on Ronald Blue Trust, Inc. with notifications on news.